Publications by authors named "Jean Hubble"

Claim this Profile
E
EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease.
Caroline M Tanner, Rajesh Pahwa, Robert A Hauser, Wolfgang H Oertel, Stuart H Isaacson, Jean Hubble

J Parkinsons Dis· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
analyses of the edaravone clinical trials Study 16 and Study 19: a step toward more efficient clinical trial designs in amyotrophic lateral sclerosis.
Joseph M Palumbo, Jean Hubble, Stephen Apple, Koji Takei, Kikumi Tsuda

Amyotroph Lateral Scler Frontotemporal Degener· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apomorphine Subcutaneous Injection for the Management of Morning Akinesia in Parkinson's Disease.
Stuart Isaacson, Mark Lew, William Ondo, Jean Hubble, Thomas Clinch

Mov Disord Clin Pract· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dysport (botulinum toxin type A) in routine therapeutic usage: a telephone needs assessment survey of European physicians to evaluate current awareness and adherence to product labeling changes.
Jean Hubble, Joseph Schwab, Catherine Hubert, Chandra Coleman Abbott

Clin Neuropharmacol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AbobotulinumtoxinA (Dysport) dosing in cervical dystonia: an exploratory analysis of two large open-label extension studies.
Robert A Hauser, Daniel Truong, Jean Hubble, Chandra Coleman, Jean-Luc Beffy

J Neural Transm (Vienna)· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunoresistance in cervical dystonia patients after treatment with abobotulinumtoxinA.
Chandra Coleman, Jean Hubble, Joseph Schwab, Jean-Luc Beffy, Philippe Picaut

Int J Neurosci· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies.
Peter A LeWitt, Danna Jennings, Kelly E Lyons, Rajesh Pahwa, Adrian L Rabinowicz, Jean P Hubble

Mov Disord· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial.
C Warren Olanow, Anthony H V Schapira, Peter A LeWitt, Karl Kieburtz, Dirk Sauer, Jean Hubble

Lancet Neurol· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term evaluation of deep brain stimulation of the thalamus.
Rajesh Pahwa, Kelly E Lyons, Steven B Wilkinson, Richard K Simpson, William G Ondo, Jean P Hubble

J Neurosurg· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
Robert G Holloway, Ira Shoulson, Stanley Fahn, Karl Kieburtz, Anthony Lang, Jean Hubble

Arch Neurol· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease.
Yi-Ju Li, Sofia A Oliveira, Puting Xu, Eden R Martin, Judith E Stenger, Jean P Hubble

Hum Mol Genet· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.
Robert A Hauser, Jean P Hubble, Daniel D Truong,

Neurology· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association study of Parkin gene polymorphisms with idiopathic Parkinson disease.
Sofia A Oliveira, William K Scott, Martha A Nance, Ray L Watts, Jean P Hubble

Arch Neurol· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of sleepiness and unintended sleep in Parkinson's disease patients taking dopamine agonists.
Thomas Roth, David B Rye, Leona D Borchert, Cindy Bartlett, Donald L Bliwise, Jean P Hubble

Sleep Med· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and testing of the Parkinson's disease quality of life scale.
Mickie Welsh, Michael P McDermott, Robert G Holloway, Sandy Plumb, Ronald Pfeiffer, Jean Hubble

Mov Disord· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Parkin mutations and susceptibility alleles in late-onset Parkinson's disease.
Sofia A Oliveira, William K Scott, Eden R Martin, Martha A Nance, Ray L Watts, Jean P Hubble

Ann Neurol· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease.
Joelle M van der Walt, Kristin K Nicodemus, Eden R Martin, William K Scott, Martha A Nance, Jean P Hubble

Am J Hum Genet· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study.
Anita L DeStefano, Mark F Lew, Lawrence I Golbe, Margery H Mark, Alice M Lazzarini, Jean P Hubble

Am J Hum Genet· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Age at onset in two common neurodegenerative diseases is genetically controlled.
Yi-Ju Li, William K Scott, Dale J Hedges, Fengyu Zhang, P Craig Gaskell, Jean P Hubble

Am J Hum Genet· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term studies of dopamine agonists.
Jean P Hubble

Neurology· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease.
Robert A Hauser, William C Koller, Jean P Hubble, Teresita Malapira, Karen Busenbark

Mov Disord· May 2000

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis